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Background: Kidney transplantation is the gold standard of therapy in patients with terminal renal insufficiency.
Living donor transplantation is a well-established option in this field. Enlarging the donor’s pool implicates the acceptance
of an increased rate of comorbidities. Among them, coronary artery disease is a growing problem. An increasing number
of patients, undergoing living donation, receive antiplatelet therapies due to coronary disease.
Case presentation: Here we report about the perioperative treatment with a drug-eluting balloon in a patient with major
cardiac risk factors who underwent kidney transplantation.
Conclusion: At the current time no recommendation can be given for the routine use of drug-eluting balloons.Background
Kidney transplantation is still the gold standard of therapy
in patients with terminal renal insufficiency. Thus, the cri-
teria for candidates for kidney transplantation have been
weakened over the last decades to offer this option to a
larger group of patients with otherwise worse outcome.
Living donor transplantation is becoming more and more
a well-established option in this field. However, clinicians
will have to deal more and more with patients suffering
from a number of relevant co-morbidities. Especially coron-
ary artery disease (CAD) is becoming a growing problem in
perioperative medicine as current standard treatment op-
tions (i.e. coronary stenting) often go along with long last-
ing antiaggregation protocols [1,2]. Various aspects of
antiaggregation after percutaneous transluminal coronary
angioplasty (PTCA) are partly discussed controversially [3].
Dual platelet inhibition after placement of drug eluting or
bare metal stents may lead to considerable bleeding compli-
cations during the surgical intervention [4,5]. By contrast
an interruption of antiplatelet therapy results in a signifi-
cant increase of perioperative cardiac complications [6,7].
At the same time, more and more drug-eluting stents are
used by interventional cardiologists. To minimise this prob-
lem a bipartite intervention using a drug-eluting balloon is* Correspondence: andres.beiras@kgu.de
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article, unless otherwise stated.a possible alternative [8-10]. Until now, no investiga-
tions or case reports are published examining the use of
drug-eluting balloons in a perioperative setting. Here
we report about the perioperative treatment with a
drug-eluting balloon in a kidney transplant patient with
major cardiac risk factors.Case presentation
A 66-year-old man (height 172 cm, weight 92 kg) pre-
sented with diabetic nephropathy for planned living
donor kidney transplantation. He suffered from CAD,
hypertension, hypercholesterolemia, insulin dependent
diabetes mellitus II and a chronic obstructive pulmonary
disease. He had undergone coronary artery bypass surgery
in a different hospital 7 months before (left internal mam-
mary artery (LIMA) to left anterior descending (LAD) and
saphenous vein graft to the ramus diagonalis). The ramus
circumflexus (RCX) was not accessible to revasculariza-
tion during bypass operation according to the documents
of the different hospital. The LAD was supplied with a
drug-eluting stent three years before. The RCX was sup-
plied with a bare-metal stent one year before and, because
of an in-stent restenosis, 5 month before with a Genous
stent in a different hospital. Additionally another Genous
stent was placed distally to the previous stent area.
The patients’ wife was intended to serve as the organ
donor. She had a history of severe chronic obstructive pul-
monary disease with intercurrent infectious exacerbation,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 2 (preoperative angiography): ramus circumflexus after
dilatation with a drug-eluting balloon.
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to the planned date of transplantation she was in good
condition.
On account of the medical history of the recipient and
according to the pre-transplantation guidelines of our
institution with regard to high-risk patients a cardiac
catheterization was carried out 5 days before transplant-
ation. Here an in-stent restenosis of the proximal ramus
circumflexus, which had already been supplied with
drug-eluting and bare metal stents two times before, was
observed (see Figure 1). After intensive discussion between
the cardiologist, the surgeon and the anaesthesiologist the
following therapeutic plan was made: the stenosis was di-
lated with a 3.0/15 mm drug-eluting balloon (Inc. Braun,
Germany) followed by anticoagulation with tirofiban and
aspirin until surgery. The post-interventional angiography
showed a very good result after PTCA (see Figure 2). De-
finitive stenting was planned after full recovery from the
kidney transplantation.
Five days later the planned kidney transplantation was
carried out. Medication including aspirin and tirofiban
was continued up to the day of operation. In the operat-
ing room (OR) induction with sufentanil 0.33 μg kg−1,
propofol 1.6 mg kg−1 and rocuronium 0.33 mg kg−1 was
performed. Anaesthesia was maintained with sevo-
fluoran 1.6 Vol%. During whole operation mean arterial
pressure was above 70 mmHg with a heart rate between
50 and 60 bpm. The patient received norepinephrine
with a maximum dose of 0.11 μg kg−1 min. Intraopera-
tive blood loss was 800 ml, and the lowest level of
haemoglobin was 12.2 g/l. The patient received 2500 ml
of crystalloid solution. After successful kidney trans-
plantation he was extubated in the OR and transferred
to the intensive care unit (ICU).Figure 1 (preoperative angiography): stenosis of the proximal
ramus circumflexus.One hour after admission to the intensive care unit
(ICU) the patient developed pectanginous symptoms. The
ECG at 10 minutes after clinical presentation of angina re-
vealed no significant abnormalities. The cardiac troponin I
was initial negative and 13.9 pg/ml after 4 hours with a
peak level of >50.0 pg/ml 7 hours after admission. Cardiac
catheterization, carried out 20 minutes after the first com-
plaint of angina by the patient presented a sub-acute in-
stent thrombosis of the RCX stent which had been dilated
preoperatively with a drug-eluting balloon (see Figure 3).
After PTCA with a 2.0 mm balloon the implantation of
a 3.0/24 mm drug-eluting stent (Medtronic Endeavor
Resolute, Medtronic, Germany) followed. The angiog-
raphy again showed a good result (see Figure 4).Figure 3 (postoperative angiography): restenosis of the
proximal ramus circumflexus.
Figure 4 (postoperative angiography): revascularization of
ramus circumflexus after placement of a drug-eluting stent.
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anticoagulation with tirofiban over 3 days was started
followed by prasugrel for 12 months and aspirin. During
anticoagulation only minor skin bleeding appeared. 12 days
after kidney transplantation the patient could be dismissed
home in a good state and is still well after three years.
Discussion
The perioperative management of patients undergoing
non-cardiac surgery in the age of increasing percutan-
eous coronary intervention is a major problem. The
present treatment is based on the recommendations of the
American College of Cardiology Foundation (ACCF) and
the American Heart Association (AHA) [11,12]. Addition-
ally, guidelines of the European Society of Cardiology
(ESC) and the European Society of Anaesthesiology (ESA)
were published in 2009 [13].
Patients, receiving a surgical intervention within the
first 35 days after coronary stent implantation, have an
increased risk of stent thrombosis with consecutively in-
creased morbidity and mortality [14]. Hence, it is recom-
mended to delay elective interventions about at least
6 weeks (after bare metal stent) [15] or 12 months (after
drug eluting stents) [16]. If this is no opinion in urgent
cases or emergency surgery, an individual, patient adapted
strategy has to be carried out. In the present case, the living
donor transplantation was called off twice because of an
infect exacerbation of the donor, who was now in a good
condition. After interdisciplinary discussion the renewed
in-stent restenosis was treated by a drug-eluting balloon,
followed by anticoagulation with tirofiban and aspirin until
surgery. Eptifibatide [17] or tirofiban [18] is a possible alter-
native to clopidogrel. If dual antiplatelet therapy is not pos-
sible on account of high bleeding risk, for example inneurosurgery, clopidogrel can be stopped 5–7 days before
surgery under current medication with aspirin [16]. Instead
of stenting with BMS or DES a pure balloon angioplasty
should be performed under specific circumstances [16].
These specific circumstances are, however, not specified in
the guideline. Thus, preoperative PTCA without stenting
seems to be a good “bridging strategy” for patients with
intermediate urgency of the planned operation. A re-
cently increasingly used alternative is an intervention
with drug eluting balloons [8-10]. Several clinical inves-
tigations underline the meaning of drug-eluting bal-
loons in the treatment of instent stenosis [19-21]. This
new option may even foster the attitude towards the
mentioned “bridging strategy”.
Conclusions
In our opinion and based on this report the use of a
drug-eluting balloon intervention should only be per-
formed under special circumstances: the whole team has
to be aware of the potential risk of perioperative myocar-
dial ischemia, and the option of immediate coronary re-
intervention by a cardiologist familiar with the respective
case has to be well prepared. In the present case it was
even the same cardiologist who had performed the initial
intervention.
This underlines the meaning of an interdisciplinary ap-
proach in the perioperative care of cardiac patients which
concerns not only surgeons and anaesthesiologists, but in
particular also the treating cardiologists.
On account of the insufficient data at the current time
from our point of view no recommendation can be given
for the routine use of drug-eluting balloons.Patient’s consent
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